News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Ties Hepatitis C Success To Rival Gilead Sciences, Inc. (GILD)'s Pill


1/15/2014 7:07:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb Co. (BMY) will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc. (GILD)’s approved pill.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES